Showing results (311-320 of 323) with videos related to
Sort By:
Pageof 33
The Journal of Pain|October 5, 2022
Optimizing and Accelerating the Development of Precision Pain Treatments for Chronic Pain: IMMPACT Review and RecommendationsRobert R Edwards, Kristin L Schreiber, Robert H Dworkin, et al.Nature Cancer|September 22, 2023
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancerSara Bobisse, Valentina Bianchi, Janos L Tanyi, et al.Nature Biotechnology|October 11, 2024
A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapyFlorian Huber, Marion Arnaud, Brian J Stevenson, et al.Immunity|September 14, 2024
Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanomaJohanna Chiffelle, David Barras, Rémy Pétremand, et al.Nature Communications|June 6, 2023
Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumorsJulien Schmidt, Johanna Chiffelle, Marta A S Perez, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2026
Combinatorial delivery of low-dose radiotherapy and immunotherapy to patients with immune-excluded tumors enhances CD8+ T cell functionalityMaria Ochoa-de-Olza, Nicolas Rayroux, Martina Imbimbo, et al.Science (New York, N.Y.)|August 3, 2023
CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancersRuben Bill, Pratyaksha Wirapati, Marius Messemaker, et al.Cancer Cell|November 5, 2021
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulationJaikumar Duraiswamy, Riccardo Turrini, Aspram Minasyan, et al.Nature|April 24, 2024
PGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial functionMatteo Morotti, Alizee J Grimm, Helen Carrasco Hope, et al.Cancer Discovery|September 4, 2021
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to ImmunotherapyFernanda G Herrera, Catherine Ronet, Maria Ochoa de Olza, et al.Pageof 33